Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth

1. CALDWELL SH., CRESPO DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004; 40(4):578-84.Search in Google Scholar

2. LONARDO A., BYRNE C., CALDWELL S., CORTEZ-PINTO H., TARGHER G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 1388-1389.10.1002/hep.28584Open DOISearch in Google Scholar

3. FAN JG., SAIBARA T., CHITTURI S., KIM BI., SUNG JJ., CHUTAPUTTI A. What are the risk factors and settings for nonalcoholic fatty liver disease in Asia–Pacific? J Gastroenterol Hepatol. 2007; 22(6):794-800.Search in Google Scholar

4. OGDEN CL., CARROLL MD., CURTIN LR., LAMB MM., FLEGAL KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010; 303(3):242-9.Search in Google Scholar

5. GAGGINI M., MORELLI M., BUZZIGOLI E., DEFRONZO RA., BUGIANESI E., GASTALDELLI A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5):1544-60.Search in Google Scholar

6. AL-BUSAFI SA., BHAT M., WONG P., GHALI P., DESCHENES M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012; 22: 947575.Search in Google Scholar

7. VIGANÒ M., VERGANI A., TROMBINI P., POZZI M., PALEARI F., PIPERNO A. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology. 2000; 118(5):986-7.10.1016/S0016-5085(00)70193-4Open DOISearch in Google Scholar

8. COHEN B., NOVICK D., RUBINSTEIN M. Modulation of insulin activities by leptin. Science. 1996; 274(5290):1185.Search in Google Scholar

9. PAPPO I., BERCOVIER H., BERRY E., GALLILLY R., FEIGIN E., FREUND HR. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. J Parenter Enteral Nutr. 1995; 19(1):80-2.Search in Google Scholar

10. KIRSCH R., CLARKSON V., VERDONK RC., MARAIS AD., SHEPHARD EG., RYFFEL B., et al. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol. 2006; 21(1):174-82.Search in Google Scholar

11. BOND JR JH., LEVITT MD. Use of pulmonary hydrogen (H2) measurements to quantitate carbohydrate absorption: study of partially gastrectomized patients. J Clin Invest. 1972; 51(5):1219.10.1172/JCI106916Open DOISearch in Google Scholar

12. SABATÉ J-M., JOUËT P., HARNOIS F., MECHLER C., MSIKA S., GROSSIN M., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008; 18(4):371-7.10.1007/s11695-007-9398-2Open DOISearch in Google Scholar

13. CORAZZA GR., STROCCHI A., GASBARRINI G. Fasting breath hydrogen in celiac disease. Gastroenterology. 1987; 93(1):53-8.Search in Google Scholar

14. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106:3143-3421.Search in Google Scholar

15. WIGG A., ROBERTS-THOMSON I., DYMOCK R., MCCARTHY P., GROSE R., CUMMINS A. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48(2):206-11.10.1136/gut.48.2.206Open DOISearch in Google Scholar

16. SHANAB AA., SCULLY P., CROSBIE O., BUCKLEY M., O’MAHONY L., SHANAHAN F., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011; 56(5):1524-34.Search in Google Scholar

17. RUIZ AG., CASAFONT F., CRESPO J., CAYÓN A., MAYORGA M., ESTEBANEZ A., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007; 17(10):1374-80.Search in Google Scholar

18. BELLOT P., FRANCÉS R., SUCH J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013; 33(1):31-9.Search in Google Scholar

19. WIEST R., LAWSON M., GEUKING M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014; 60(1):197-209.Search in Google Scholar

20. GUPTA A., DHIMAN RK., KUMARI S., RANA S., AGARWAL R., DUSEJA A., et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010; 53(5):849-55.10.1016/j.jhep.2010.05.017Open DOISearch in Google Scholar

21. MIELE L., VALENZA V., LA TORRE G., MONTALTO M., CAMMAROTA G., RICCI R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6):1877-87.Search in Google Scholar

22. PARNELL JA., RAMAN M., RIOUX KP., REIMER RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32(5):701-11.10.1111/j.1478-3231.2011.02730.xOpen DOISearch in Google Scholar

23. XU R-Y., WAN Y-P., FANG Q-Y., LU W., CAI W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2011; 50(1):72-7.Search in Google Scholar

24. PARLESAK A., KLEIN B., SCHECHER K., BODE JC., BODE C. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc. 2003; 51(6):768-73.10.1046/j.1365-2389.2003.51259.xOpen DOISearch in Google Scholar

25. ALKHOURI N., CIKACH F., ENG K., MOSES J., PATEL N., YAN C., et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroenterol Hepatol. 2014; 26:82-7.Search in Google Scholar

• A Practical Review of Diabetes Mellitus Type 2 Treatment in Primary Care

• Lupus-related protein-losing enteropathy associated with pseudo–pseudo Meigs’ syndrome and successfully treated with hydroxychloroquine

• COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant

• The Frailty Phenotype in Hemodialysis Patients and its Association with Biochemical Markers of Mineral Bone Disorder, Inflammation and Nutrition

• Hyper-inflammation after COVID-19 mARN vaccination: at the crossroads of multisystem inflammatory disease and adult-onset Still’s disease. Does terminology matter?

• Non secretory myeloma in young man mimicking the Gorham disease: case report and the literature review

• Association between admission blood glucose and prognosis in non-diabetic patients with first-ever acute myocardial infarction

• Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

• Anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis caused by bacterial organizing pneumonia in a patient with Sjogren syndrome

• Acute myelogenous leukemia – current recommendations and approaches in molecular-genetic assessment

• Peculiar encounter of sarcoidosis and solid pseudopapillary tumor of the pancreas

• Systematic Approach to Celiac Disease: A Comprehensive Review for Primary Providers

• The role of thyroid hormones in carotid arterial wall remodeling in women

• Serum Uric Acid as a Predictor of cardio-and cerebro-vascular diseases in Maintenance Hemodialysis Patients

• Anti - Dense Fıne Speckled (DFS) Antibody: its staınıng pattern in indirect immunofluorescence and its clinical relevance

• Cardiac biomarkers alterations in patients with SARS-CoV-2 infection

• Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience

• Autoimmune Polyglandular Syndrome Type II presenting as Subacute Combined Degeneration of Spinal Cord: A Neuroendocrinology Crossroad

• Erratum for the paper Erfani A. Liver Fibrosis: Causes and Methods of Assessment, A Review. Rom J Intern Med. 2015;53(4):304-14.